The United Kingdom and the United States have reached a key bilateral deal that will guarantee zero import taxes on UK pharmaceutical exports going into the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to increase spending on pharmaceuticals through the NHS. This commitment ensures that import taxes on these key products will remain at nothing for a period of 36 months.
This deal comes after previous statements to dramatically increase tariffs on patented drug imports, with potential rates mentioned reaching one hundred percent.
"This deal between the United Kingdom bolsters the global environment for cutting-edge drugs and brings long-overdue equity to transatlantic drug exports," a release said.
Trade Importance
Pharmaceuticals are one of the Britain's largest goods shipped to the United States, which is by far the biggest market for major companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to last September, the UK sold pharmaceutical products totaling £11.1bn to the US. This value represented nearly one-fifth of all goods exports in that span.
"This agreement secures employment, increases investment and paves the way for the UK to become a global hub for medical research," a minister commented.
Detailed British Pledges
The deal entails several specific pledges from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The amount drug companies must refund to the NHS to prevent overspending will be capped at 15%. Last year, rebates exceeded twenty percent.
Broader Context
This agreement follows a ongoing dispute between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
This friction were exacerbated by assertions that American customers were charged several times more for the identical medicines than patients in the other developed nations.
Recently, several large drug company projects in the UK have been halted or cancelled, while substantial funding commitments have been directed toward American operations.
The Science Minister acknowledged that the NHS must increase expenditure on drugs, noting that its spending on drugs had decreased as a proportion of its total funding over the last ten years.
